19 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver
The Phase 2a HERALD study was initiated in Q1 2024
PRE 14A
ALGS
Aligos Therapeutics Inc
16 Apr 24
Preliminary proxy
5:27pm
the engagement is entered into pursuant to appropriate additional pre-approval policies established by the Audit Committee. This policy is set forth … registered public accounting firm’s qualifications, independence and performance;
determines the terms of engagement of the independent registered public
8-K
EX-10.1
ALGS
Aligos Therapeutics Inc
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
as the “Securities.”
WHEREAS, in connection with the offering and sale of the Shares and the Warrants, the Company has entered into an engagement letter, dated
DEF 14A
f7fy qky5
27 Apr 21
Definitive proxy
4:15pm
8-K
EX-3.2
8gl5t
20 Oct 20
Amendments to Articles of Incorporation or Bylaws
4:03pm
424B4
9m8q 6hyssjic9lcac4
19 Oct 20
Prospectus supplement with pricing info
5:21pm
S-1
qxdp8
25 Sep 20
IPO registration
5:27pm
S-1
EX-10.3
qd7bf6tw
25 Sep 20
IPO registration
5:27pm
DRS
o8gle9
26 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next